Effectiveness, tolerability and response predictors of preventive anti-CGRP mAbs for migraine in patients over 65 years old: a multicenter real-world case-control study
Abstract
OBJECTIVE
To evaluate clinical characteristics, effectiveness, and tolerability of preventive anti-CGRP mAbs in the elderly. Anti-CGRP mAbs have demonstrated efficacy and safety in patients with migraine although there is limited information regarding the elderly.
DESIGN
We performed a multicenter case-control study of cases(patients over 65 years old) and controls(sex-matched patients under 55 years old) with migraine receiving anti-CGRP mAbs.
METHODS
We included the demographic characteristics, effectiveness-reduction in the number of monthly headache days(MHD) and monthly migraine days(MMD),30%,50% and 75% responder rates- and treatment emergent adverse events(TEAEs);the primary endpoint was the 50% response rate regarding MHD at weeks 20-24; exploratory 50% response predictors in the elderly were evaluated.
RESULTS
228 patients were included-114 cases,114 controls-. Among cases 84.2%(96/114) were women,79.8%(91/114)CM;mean age of cases 70.1 years old(range:66-86);mean age of controls was 42.9 years old(range:38-49). Cases had a higher percentage of vascular risk factors(p < 0.05),older age of onset(p < 0.001) and more reported prior preventive treatments(p < 0.001). Regarding effectiveness, in cases, 50% response rate was achieved by 59.2%(90/152) at 20-24 weeks, with lower reduction in the MHD at 8-12 weeks [5(7.2),8(9.1);p=0.001] and a higher reduction in MMD at 20-24 weeks [10.7(9.1), 9.2(7.7);p=0.04] compared to the control group. The percentage of a TEAEs was…
How strong is the evidence?
Evidence Hub reads this as a case-control, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 228 participants or records.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.